Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial.

The trial met its primary endpoint. On day 8, the MADRS score had fallen by a mean of 7.27 points more in the psilocybin group than in the niacin group (95% CI -12.89 to -1.65; P = .01). The text indicates that the between-group difference remained significant at later short-term follow-up points, with superiority reported through day 42, but not at day 365 on the clinician-rated MADRS. The self-report MADRS-S showed a longer duration of effect, with significant differences reported until day 102 in the intention-to-treat analysis. When participants were censored at antidepressant initiation, the self-report duration of effect shortened to day 72. For follow-up treatment use, antidepressant initiation did not differ significantly between groups: 6 participants in the psilocybin group and 7 in the niacin group started antidepressants during follow-up. Among those who initiated treatment, mean time to antidepressant initiation was 130.0 days in the psilocybin group and 128.0 days in the niacin group (P = .70). The paper reports that secondary outcomes were broadly consistent with sustained symptom improvement. Health-related quality of life and functional disability measures favoured psilocybin, and the authors note that response and remission patterns were also supportive of benefit, although the detailed figures for all secondary outcomes are not fully reproduced in the extracted text. The text states that the 12-month MADRS remission rate in the intention-to-treat population was 52.9% for psilocybin and 41.2% for niacin. The niacin group’s remission rate rose from 11.8% to 41.2% over the study period, while the psilocybin group maintained a high remission rate from day 8 onwards. Safety findings were generally reassuring but not without concern. Psilocybin was described as mostly producing transient treatment-emergent adverse events of mild to moderate severity. However, 2 participants experienced severe, persistent anxiety that required medical attention. Expectancy before dosing was similar between groups, with mean scores of about 56.7 and 56.8 on a 0 to 100 scale. Psychedelic intensity was much higher in the psilocybin group than in the niacin group. Blinding was poor in both groups: participants correctly guessed allocation in 94.1% of psilocybin cases and 100% of niacin cases, while the blinded rater guessed correctly in 82.4% and 76.5%, respectively.

The authors interpret the findings as evidence that a single 25-mg dose of psilocybin produced a clinically meaningful and rapid reduction in depressive symptoms in MDD, with benefit apparent by day 8 and persisting for several weeks. They argue that the study adds more rigorous placebo-controlled evidence to a field in which previous studies often lacked long-term control groups or were vulnerable to selection and expectancy bias. They also state that the pattern of results supports the possibility that psilocybin could complement existing treatments when rapid symptom relief is important. Compared with earlier research, the authors suggest that their trial adds nuance by showing both a short-term antidepressant effect and a longer, but not indefinite, follow-up signal. They note that the duration of benefit may be shorter than that implied by some uncontrolled studies, and they raise the possibility that repeated dosing or maintenance treatment might be needed to prevent relapse. They also point out that the improvement seen in the niacin group is consistent with the episodic nature of depression and the possibility of spontaneous remission, which may have inflated durability estimates in uncontrolled work. A major theme of the discussion is blinding. The authors conclude that niacin did not provide satisfactory blinding in this psychedelic-naive sample, because psilocybin produced unmistakable subjective effects and both participants and raters often guessed allocation correctly. They suggest that expectancy, subjective psychedelic intensity, and functional unblinding may all have influenced the observed effect size, and they emphasise that disentangling direct pharmacological effects from these indirect influences remains an important task for future research. The authors also discuss safety and tolerability. Psilocybin was generally well tolerated, but the occurrence of severe persistent anxiety in 2 participants indicates that some patients may need additional support. They acknowledge several limitations: the modest sample size, possible baseline imbalance including more prior SSRI use in the niacin group, recruitment through social media with attendant self-selection and expectancy bias, the subjective nature of the outcome measures, and the possibility that using study physicians as blinded raters reduced blinding integrity. They also note that the study was powered for the primary outcome rather than the longer-term secondary endpoints, so long-term conclusions remain tentative.

The authors conclude that a single 25-mg dose of psilocybin led to a clinically meaningful reduction in depressive symptoms compared with niacin, with improvement already evident by day 8. They state that psilocybin may be an option to standard treatments when rapid symptom relief is needed, while also noting that the superiority over niacin did not persist indefinitely and was no longer seen on the clinician-rated outcome at 12 months.